Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression

This study has been completed.
Duke University
Information provided by:
Stanford University Identifier:
First received: January 31, 2006
Last updated: May 16, 2008
Last verified: May 2008
This is an 8 week study for patients who are currently taking antidepressant medication but not fully responding. Ropinirole CR would be taken in conjunction with current antidepressant medication. Patients come into the clinic once a week when starting on the medication and then once every other week for the remainder of the 8 weeks.

Condition Intervention
Depressive Disorder, Major
Drug: Ropinirole CR

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • HamD

Secondary Outcome Measures:

Estimated Enrollment: 60
Study Start Date: January 2006
Estimated Study Completion Date: October 2007
Detailed Description:
We hope to learn whether ropinirole CR (controlled release formulation) is safe and effective when taken with an antidepressant to reduce the symptoms of depression. Adults who have a diagnosis of major depression and are currently taking an adequate dose of antidepressant medication will be sought for participation. They will continue to take the antidepressant medication and will receive ropinirole CR, an investigational medication, for eight weeks during which information will be collected about mood and cognitive functioning.

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 to 65 years old
  • Currently experiencing major depression
  • On at least an adequate dose of fluoxetine, paroxetine, sertraline, citalopram, escitalopram, venlafaxine, bupropion, mirtazapine or duloxetine for at least 6 weeks (monotherapy). Exclusion Criteria:1. Pregnant females or females of child bearing years not using adequate birth control in the opinion of the investigators
  • Known sensitivity to ropinirole
  • Significant medical conditions that would preclude safe participation in the study in the opinion of the investigators.
  • Significant abnormalities observed in screening laboratory evaluation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00285727

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Depression Research Clinic, Psychiatry Department, Stanford School of Medicine
Stanford, California, United States, 9430
Sponsors and Collaborators
Stanford University
Duke University
Principal Investigator: Charles Debattista Depression Research Clinic, Psychiatry Department, Stanford School of Medicine
  More Information

No publications provided Identifier: NCT00285727     History of Changes
Other Study ID Numbers: 2969 
Study First Received: January 31, 2006
Last Updated: May 16, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Behavioral Symptoms
Mental Disorders
Mood Disorders
Anti-Dyskinesia Agents
Antiparkinson Agents
Central Nervous System Agents
Dopamine Agents
Dopamine Agonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on February 11, 2016